Boston Scientific Gets FDA OK for Vercise Genus Deep Brain Stimulation System

By Colin Kellaher

Boston Scientific Corp. on Friday said the U.S. Food and Drug Administration approved its fourth-generation Vercise Genus Deep Brain Stimulation System, used to reduce motor symptoms associated with Parkinson's disease.

The Marlborough, Mass., maker of medical devices said the portfolio, approved for conditional use in a magnetic-resonance-imaging environment, consists of a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators that power Cartesia directional leads.

Boston Scientific said the Vercise Genus system can treat the symptoms of Parkinson's, a neurodegenerative disorder marked by stiffness, slowness and tremors, by delivering targeted electrical stimulation via surgically-implanted leads in the brain connected to an implantable pulse generator.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 22, 2021 07:32 ET (12:32 GMT)

Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024